StockData
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc. (CATX) stock

CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)

Close on Nov 20, 2026Market cap $86.05MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$86.05M
P/E ratio
–
Price to sales
–
Price to book
0.27
Dividend yield
–
Free cash flow yield
-140.84%

Fundamentals

Net income
-$116.43M
EPS, diluted
-$1.32
Free cash flow
-$121.19M
Book value per share
$2.68
Diluted shares
121M

Trading

Next earnings
Mar 15, 2027 (estimated, after the close)
Previous close
$0.78
Open
$0.76
Day's range
$0.74 – $0.79
Volume
1,396,520
Average volume (20 days)
4,419,320
Index membership
Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
Beta (5 years)
1.11
52-week range
$0.73 – $6.16
RSI (14 days)
25.4
Volatility (1 year)
112.2%
Relative volume
0.63×
WACC
10.5%

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.

PeriodCATXS&P 500DifferenceCATX per yearS&P 500 per year
1 month-67.2%-10.3%−56.9 pts
3 months-76.5%-9.3%−67.2 pts
Year to date-72.6%+1.9%−74.5 pts
1 year-64.4%+6.9%−71.3 pts
3 years-69.8%+57.5%−127.3 pts-32.9%+16.3%
5 years-84.6%+57.3%−141.9 pts-31.2%+9.5%
10 years-86.8%+269.7%−356.5 pts-18.3%+14.0%

Fifteen years at a glance

Fiscal years 2010 to 2025 and trailing twelve months, USD

Revenue

–

Gross profit

–

Operating income

-$125.23M

Net income

-$116.43M

EPS, diluted

-$1.32

Free cash flow

-$121.19M
Reported periodTrailing twelve months

Press releases

Releases Perspective Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Perspective Therapeutics

Pharmaceutical Preparations

Perspective Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapies and alpha-particle therapeutic drug candidates to treat serious diseases. Its pipeline of investigational drug product candidates includes PSV359, VMT-α-NET, and VMT01, which are undergoing research and clinical evaluation. The company conducts research, clinical development, and finishing operations for its therapeutic assets, supported by subsidiaries including Viewpoint Molecular Targeting, Inc. and Isoray Medical, Inc. Its intended end users and customers encompass patients participating in clinical trials, physicians, healthcare payors, and major treatment centers.

Company profile, executives and history

Perspective Therapeutics stock: common questions

What is Perspective Therapeutics's stock price?

CATX closed at $0.75 on Nov 20, 2026, down 3.85% on the day. Over the past 52 weeks it traded between $0.73 and $6.16.

What is Perspective Therapeutics's market cap?

Perspective Therapeutics was worth $86.05M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.

What is CATX's P/E ratio?

Perspective Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.32), so it has no meaningful P/E ratio.

Does Perspective Therapeutics pay a dividend?

No. Perspective Therapeutics has not paid a cash dividend over the last twelve months.

When does Perspective Therapeutics report earnings next?

Perspective Therapeutics is expected to report Q4 FY2026 results on Mar 15, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has CATX stock performed over the past year?

Including dividends, CATX returned -64.4% over the past year, against +6.9% for the S&P 500.

How many CATX shares are sold short?

9M shares were sold short at the latest FINRA report, 8.58% of the float, or 2.5 days of average trading volume.

Who are Perspective Therapeutics's competitors?

Companies most similar to Perspective Therapeutics by business, industry and size include CLRB, COGT, NBP, APVO, PHIO.

See a number that looks wrong?